The form was uploaded to medical-data-models.org - Original URL: https://medical-data-models.org/15419
StudyName: ToFingo Screening V1 Patient Information Background Information NCT02325440
Date of export from the portal: 02.07.2020
Date of Upload / last change: 31.05.2016
License: Creative Commons BY 4.0

----

Description: 
Principal Investigator: Luisa Klotz
Collaborator: Novartis
Information provided by (Responsible Party):University Hospital Muenster

-Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya (ToFingo2)

Purpose 

A trial in patients with relapsing remitting multiple sclerosis (RRMS)

Main objectives:
•To evaluate changes in the reconstitution of immune surveillance over time upon switching from natalizumab to fingolimod assessed by a change in the expression of CD49d.
•To evaluate changes in the migratory capacity of immune cells/peripheral blood mononuclear cells (PBMCs) upon switching from natalizumab to fingolimod in an in-vitro model of the blood-brain-barrier (BBB).
•To evaluate changes in paraclinical disease activity over time upon switching from natalizumab to fingolimod assessed by MRI (changes in Gd+, T2w lesions and DTI).
•To evaluate changes in T1w / FLAIR lesions upon switching from natalizumab to fingolimod.

For further Information please visit https://clinicaltrials.gov/ct2/show/NCT02325440
